MAIN BODY
Suppression of central neuroinflammation and sustained clinical fatigue alleviation
The detailed mid-stage clinical results validate Foralumab’s novel therapeutic mechanism in modulating central nervous system microenvironment inflammation. Patients receiving the 50-microgram intranasal regimen exhibited pronounced dampening of pathological neuroinflammatory activity compared to parallel control cohorts on placebo.
*"Patients receiving the treatment Foralumab showed clinically meaningful reductions in fatigue after 12 weeks, while the placebo group did not." — Clinical Research Directorate of Tiziana Life Sciences












